摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-2-chlorobenzonitrile | 1189140-57-5

中文名称
——
中文别名
——
英文名称
4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-2-chlorobenzonitrile
英文别名
4-(4-bromo-3,5-dimethylpyrazol-1-yl)-2-chlorobenzonitrile
4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-2-chlorobenzonitrile化学式
CAS
1189140-57-5
化学式
C12H9BrClN3
mdl
MFCD17410969
分子量
310.581
InChiKey
PSVNVRTZBWLZRH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    41.6
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-2-chlorobenzonitrile4-氟苯硼酸sodium carbonate 作用下, 以 二甲氧基乙烷 为溶剂, 反应 0.18h, 以20%的产率得到2-chloro-4-[4-(4-fluorophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]benzonitrile
    参考文献:
    名称:
    Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists
    摘要:
    A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R-2) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2012.02.005
  • 作为产物:
    描述:
    2-氯-4-氟苯腈 、 sodium hydride 、 溶剂黄146 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 生成 4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-2-chlorobenzonitrile
    参考文献:
    名称:
    [EN] SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF
    [FR] DÉRIVÉS PYRAZOLE SUBSTITUÉS ET LEUR UTILISATION
    摘要:
    本发明旨在提供由式(I')表示的吡唑衍生物或其盐。
    公开号:
    WO2009119880A1
点击查看最新优质反应信息

文献信息

  • Substituted pyrazole derivatives and use thereof
    申请人:Ito Mitsuhiro
    公开号:US20090270361A1
    公开(公告)日:2009-10-29
    The present invention aims to provide a novel pyrazole derivative and a pharmaceutical agent containing the same. The present invention provides a compound represented by the formula (I′) wherein R 1 ′ is (1) a hydrogen atom, (2) a group via a carbon atom, (3) a group via a nitrogen atom, (4) a group via an oxygen atom or (5) a group via a sulfur atom; R 2 ′ is an aromatic ring group optionally having substituent(s); R 3 ′ is (1) a hydrogen atom, (2) a group via a carbon atom, (3) a group via a nitrogen atom, (4) a group via an oxygen atom or (5) a group via a sulfur atom; R 4 ′ is a cyanophenyl group optionally having substituent(s); X′ is (1) —Y′—CR 5 ′R 6 ′-Z′- wherein R 5 ′ and R 6 ′ are the same or different and each is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom, or —CR 5 ′R 6 ′— is —C(alkylidene)-; Y′ is a bond, —COCO—, —CONH—, —COCONH— or —O—; and Z′ is a bond, —CH 2 —, —CONH—, —O—, —OCH 2 —, —S—, —SO—, —SO 2 —, —CON(C 6 H 5 )— or (2) —CO(CONH) n — wherein n is 0 or 1, (3) —NHCO—, (4) —CONH—, (5) —O—, (6) —CH═CH— or (7) —O(C 1-3 alkylene)O—; (excluding the compounds indicated to be excluded from the specification), or a salt thereof.
    本发明旨在提供一种新型吡唑生物及其制备的药物。本发明提供一种化合物,其表示为公式(I'): 其中,R1'是(1)原子,(2)通过原子的基团,(3)通过原子的基团,(4)通过原子的基团或(5)通过原子的基团;R2'是芳香环基团,可选地具有取代基;R3'是(1)原子,(2)通过原子的基团,(3)通过原子的基团,(4)通过原子的基团或(5)通过原子的基团;R4'是基团,可选地具有取代基;X'是(1)-Y'-CR5'R6'-Z'-,其中R5'和R6'相同或不同,每个都是原子,通过原子的基团,通过原子的基团,通过原子的基团或通过原子的基团,或者-CR5'R6'-是-C(烷基亚基)-;Y'是键,-COCO-,-CONH-,-COCONH-或-O-;Z'是键,-CH2-,-CONH-,-O-,-O -,-S-,-SO-,-SO2-,-CON(C6H5)-或(2)-CO(CONH)n-,其中n为0或1,(3)-NHCO-,(4)-CONH-,(5)-O-,(6)-CH═CH-或(7)-O(C1-3烷基亚基)O-;(不包括规范中指定要排除的化合物)或其盐。
查看更多